P.1.191: FACTORS INFLUENCING MUCOSAL HEALING IN CROHN'S DISEASE DURING INFLIXIMAB TREATMENT IN CLINICAL PRACTICE

2011 ◽  
Vol 43 ◽  
pp. S211
Author(s):  
A. Tursi ◽  
W. Elisei ◽  
G. Giorgetti ◽  
A. Penna ◽  
P.G. Lecca ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Clinical Practice ◽  
Crohn's Disease ◽  
Mucosal Healing ◽  
Infliximab Treatment ◽  
Factors Influencing

scholarly journals Targeting mucosal healing in Crohn’s disease: what the clinician needs to know

2019 ◽  
Vol 12 ◽  
pp. 175628481985686 ◽  
Author(s):  
Entcho Klenske ◽  
Christian Bojarski ◽  
Maximilian Waldner ◽  
Timo Rath ◽  
Markus F. Neurath ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Clinical Practice ◽  
Crohn's Disease ◽  
Clinical Management ◽  
Imaging Techniques ◽  
Treatment Options ◽  
Mucosal Healing ◽  
Ongoing Debate ◽  
Definition Of

In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn’s disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which reportedly are able to induce mucosal healing, the practising physician is left to wonder: how is endoscopic mucosal healing exactly defined in Crohn’s disease, and how can it effectively be achieved and monitored in daily clinical practice? Within this review, we will give an overview of the ongoing debate about the definition of mucosal healing and the modalities to monitor inflammation, and finally present available therapies with the capacity to induce mucosal healing.

Factors influencing long-term outcome of infliximab treatment in Crohn's disease

2003 ◽  
Vol 124 (4) ◽  
pp. A527
Author(s):  
Ritu Sachdev ◽  
Peter A. Banks ◽  
Jacqueline L. Wolf ◽  
Lisa L. Strate ◽  
Sonia Friedman
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Infliximab Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Factors Influencing

scholarly journals Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn’s disease

2020 ◽  
Vol 13 ◽  
pp. 175628482097692
Author(s):  
Yaling Wu ◽  
Lei Zhang ◽  
Jingli Cao ◽  
Haichao Wang ◽  
Chen Ye ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Terminal Ileum ◽  
Transverse Colon ◽  
Mucosal Healing ◽  
Treat To Target ◽  
Infliximab Treatment ◽  
Right Colon ◽  
Single Center Study ◽  
The Right

Background: Mucosal healing (MH) is the key aim of the treat-to-target strategy for patients with Crohn’s disease (CD). The efficacy of infliximab (IFX) on MH in different ileocolonic segments is unclear. The aim of this study was to investigate endoscopic MH in different ileocolonic segments in patients with CD who received IFX treatment. Methods: A retrospective, single-center study was performed in patients with active ileocolonic CD between January 2012 and December 2018. All patients underwent IFX treatment for at least 30 weeks. The MH of five ileocolonic segments was assessed by the Simple Endoscopic Score for CD (SES-CD) at baseline, 14/22 weeks and 30/38 weeks. The SES-CD values were analyzed by a mixed-effects model after the correction for confounding factors. Results: A total of 101 eligible patients were included. The baseline endoscopic severity was similar across segments. At 30/38 weeks, the greatest changes in the SES-CD ulcer size and ulcerated surface subscores were −94.29% and −94.32% both in the transverse colon ( p < 0.0001), and the smallest changes were −67.88% and −69.67% both in the terminal ileum ( p < 0.0001) compared with baseline. Stenosis mainly presented in the right colon (12/29, 41.38%). The change in the SES-CD stenosis subscore was −6.25% in the right colon at 30/38 weeks compared with −71.88% at 14/22 weeks ( p = 0.0030). At 30/38 weeks, the transverse colon achieved the highest rate of complete MH (CMH) at 81.2%, and the lowest CMH rate occurred in the terminal ileum at 45.6%. Moreover, the degree of improvement in the rectum was negatively correlated with disease progression ( p = 0.011). Conclusions: Ileocolonic segments in CD presented different degrees of endoscopic MH during IFX treatment. The transverse colon showed the highest CMH rate, whereas the right colon with stenosis showed the poorest improvement. The differing propensities of ileocolonic segments may provide an individualized IFX treatment strategy.

Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn’s Disease

2018 ◽  
Vol 61 (6) ◽  
pp. 706-712 ◽  
Author(s):  
Weisong Shen ◽  
Lei Cao ◽  
Yi Li ◽  
Xingchen Cai ◽  
Yuanyuan Ge ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Visceral Fat ◽  
Mucosal Healing ◽  
Infliximab Treatment

scholarly journals Combination of Serological Biomarkers and Clinical Features To Predict Mucosal Healing in Crohn’s Disease: A Multicenter Cohort Study

2021 ◽  
Author(s):  
Nana Tang ◽  
Han Chen ◽  
Ruidong Chen ◽  
Wen Tang ◽  
Hongjie Zhang
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Statistical Significance ◽  
Mucosal Healing ◽  
Infliximab Treatment ◽  
Clinical Tool ◽  
Multicenter Cohort Study ◽  
Reactive Protein ◽  
Primary Model ◽  
Serological Biomarkers

Abstract Background Mucosal healing (MH) has become the treatment goal of patients with Crohn’s disease (CD). This study aims to develop a noninvasive and reliable clinical tool for individual evaluation of mucosal healing in patients with Crohn’s disease. Results The following variables were independently associated with the MH and were subsequently included into the prediction model: PLR (platelet to lymphocyte ratio), CAR (C-reactive protein to albumin ratio), ESR (erythrocyte sedimentation rate), HBI (Harvey-Bradshaw Index) score and infliximab treatment. A primary model and a simple model were established, respectively. The primary model performed better than the simple one in C-index (87.5% vs 83.0 %, p=0.004). There was no statistical significance between these two models in sensitivity (70.43% vs 62.61%, p=0.467), specificity (87.12% vs 80.69%, p=0.448), PPV (72.97% vs 61.54%, p=0.292), NPV (85.65% vs 81.39%, p=0.614), and accuracy (81.61% vs 74.71%, p=0.303). The primary model had good calibration and high levels of explained variation and discrimination in validation cohort. Conclusions This model can be used to predict MH in post-treatment CD patients. It can also be used as an indication of endoscopic surveillance to evaluate mucosal healing in patients with CD after treatment.

Transabdominal bowel sonography modifications in patients with active Crohn's disease before and after infliximab treatment

2001 ◽  
Vol 120 (5) ◽  
pp. A273-A273
Author(s):  
C SERRA ◽  
P GIONCHETTI ◽  
L VOLPE ◽  
C MORELLI ◽  
M CAMPIERI ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Infliximab Treatment ◽  
Before And After ◽  
Bowel Sonography
Sign in / Sign up

Export Citation Format

Share Document